Climb Bio, Inc. financials

CLYM CIK 0001768446

Source: EDGAR filings · Built 2026-06-03T02:25:17Z

Custom taxonomy namespace: ffd

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Free Cash Flow -54.54M -15.56M -20.60M
EBITDA -67.79M -82.02M
Working Capital 98.86M 149.94M 107.42M 128.30M 142.22M 18.93M
Net Debt -35.14M -86.70M -92.76M -43.10M -46.92M
Return on Equity (ROE) -37.30% -34.88% -32.64% -35.15% -28.40% 82.73%
Return on Assets (ROA) -35.68% -34.02% -31.79% -33.52% -27.41% -83.91%
Current Ratio 15.16× 31.41× 38.92× 22.04× 24.58× 7.18×
Debt-to-Equity 0.00× 0.00× 0.00× 0.00× 0.00×
Cash Conversion Ratio 0.91× 0.21× 0.59× 0.83× 0.76× 0.68×
Accruals Ratio -0.03× -0.27× -0.13× -0.06× -0.07× -0.27×
CapEx Coverage -292.24×
Free Cash Flow Per Share $-0.80 $-0.32 $-0.76

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
P/B 1.19× 0.57× 0.70× 0.76× 1.66×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Research and Development Expense 46.71M 14.34M 15.41M 26.21M 23.32M 8.77M
Operating Expenses 67.88M 82.02M 40.27M 45.13M 35.67M 20.93M
Operating Income (Loss) -67.88M -82.02M -40.27M -45.13M -35.67M -20.93M
Income Tax Expense (Benefit) 0 0 0 0 0 0
Net Income (Loss) Attributable to Parent -59.85M -73.90M -35.12M -45.24M -47.48M -20.67M
Earnings Per Share, Basic $-0.88 $-1.53 $-1.30 $-1.72 $-4.24
Weighted Average Number of Shares Outstanding, Basic 67.81M 48.16M 26.99M 26.31M 12.26M
Earnings Per Share, Diluted $-0.88 $-1.53 $-1.30 $-1.72 $-4.24
Weighted Average Number of Shares Outstanding, Diluted 67.81M 48.16M 26.99M 26.31M 12.26M 2.19M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Cash and Cash Equivalents, at Carrying Value 35.69M 87.23M 93.11M 43.59M 46.92M 20.49M
Assets, Current 105.85M 154.87M 110.25M 134.39M 148.25M 22.00M
Assets 167.74M 217.19M 110.47M 134.99M 173.24M 24.63M
Liabilities, Current 6.98M 4.93M 2.83M 6.10M 6.03M 3.06M
Liabilities 7.27M 5.31M 2.87M 6.28M 6.04M 3.06M
Stockholders' Equity Attributable to Parent 160.47M 211.88M 107.60M 128.72M 167.20M -24.98M
Common Stock, Shares, Outstanding 47.77M 67.26M 27.70M 26.57M 26.57M 3.42M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Net Cash Provided by (Used in) Operating Activities -54.36M -15.56M -20.60M -37.37M -36.07M -14.10M
Payments to Acquire Property, Plant, and Equipment 186.00K 0
Net Cash Provided by (Used in) Investing Activities 2.83M -121.09M 68.98M 34.44M -114.97M 8.08M
Net Cash Provided by (Used in) Financing Activities -21.00K 130.73M 841.00K 0 177.23M 4.92M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (CLYM CIK 0001768446), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

COYA

Coya Therapeutics, Inc.

MAS

Masco Corporation

TMP

Tompkins Financial Corp